Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
暂无分享,去创建一个
Zhuyin Li | D. Seiffert | D. Gordon | M. Cvijic | S. Prenner | J. Chirinos | Lei Zhao | J. Mazurek | P. Zamani | Zhaoqing Wang | M. Basso | Priyanka T. Bhattacharya | Melissa Yarde | Anupam Kumar | Thomas E. Spires
[1] Akshay S. Desai,et al. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial , 2018, Circulation. Heart failure.
[2] Akshay S. Desai,et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction , 2018, European heart journal.
[3] Y. Takeishi,et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction , 2017, ESC heart failure.
[4] K. Chayama,et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease , 2016, Scientific Reports.
[5] Sanjiv J. Shah,et al. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. , 2014, JACC. Heart failure.
[6] Sanjiv J Shah,et al. Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.
[7] Sanjiv J. Shah,et al. Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2014, Circulation. Heart failure.
[8] Carmen Cadarso-Suárez,et al. smoothHR: An R Package for Pointwise Nonparametric Estimation of Hazard Ratio Curves of Continuous Predictors , 2013, Comput. Math. Methods Medicine.
[9] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[10] Karl Swedberg,et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.
[11] A. Coats,et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction , 2012, European journal of heart failure.
[12] Akshay S. Desai,et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. , 2011, American heart journal.
[13] G. Filippatos,et al. Hypoalbuminaemia and incident heart failure in older adults , 2011, European journal of heart failure.
[14] D. Phelan,et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? , 2011, European journal of heart failure.
[15] C. Tschöpe,et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. , 2011, Journal of the American College of Cardiology.
[16] P. Steendijk,et al. Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.
[17] S. Moore,et al. Serum albumin and mortality in acutely decompensated heart failure. , 2010, American heart journal.
[18] G. Fonarow,et al. Albumin levels predict survival in patients with systolic heart failure. , 2008, American heart journal.
[19] T. Therneau,et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.
[20] H. Müller,et al. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. , 2004, Kidney international.
[21] I. Kushner,et al. Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.
[22] B. Kestenbaum,et al. Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] Yongmei Liu,et al. Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study , 2009 .
[24] A. Burt,et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .